GYKI 52466: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
== GYKI 52466 == | |||
[[File:GYKI_52466.svg|thumb|right|Chemical structure of GYKI 52466]] | |||
'''GYKI 52466''' is a chemical compound known for its role as a non-competitive [[AMPA receptor]] antagonist. It is primarily used in [[neuroscience]] research to study the effects of AMPA receptor inhibition on [[synaptic transmission]] and [[neuroprotection]]. | |||
== | == Mechanism of Action == | ||
== | GYKI 52466 functions by binding to the AMPA receptor, a type of [[ionotropic glutamate receptor]] in the [[central nervous system]]. Unlike competitive antagonists, GYKI 52466 does not compete with [[glutamate]] for binding at the receptor's active site. Instead, it binds to an allosteric site, causing a conformational change that reduces the receptor's activity. This non-competitive inhibition results in decreased [[excitatory synaptic transmission]], which can be beneficial in conditions characterized by excessive neuronal excitation. | ||
== Applications in Research == | |||
In [[neuroscience research]], GYKI 52466 is utilized to explore the role of AMPA receptors in various physiological and pathological processes. It has been instrumental in studies investigating [[epilepsy]], [[ischemic stroke]], and [[neurodegenerative diseases]] such as [[Alzheimer's disease]]. By inhibiting AMPA receptor activity, researchers can assess the contribution of these receptors to [[neuronal excitotoxicity]] and [[cell death]]. | |||
== Potential Therapeutic Uses == | |||
The neuroprotective properties of GYKI 52466 have sparked interest in its potential therapeutic applications. In preclinical models, it has shown promise in reducing [[neuronal damage]] following [[ischemic events]] and in mitigating [[seizure]] activity. However, further research is needed to evaluate its safety and efficacy in humans. | |||
== Chemical Properties == | |||
GYKI 52466 is a member of the [[2,3-benzodiazepine]] family, characterized by its unique chemical structure that allows for selective inhibition of AMPA receptors. The compound's structure is depicted in the accompanying image, highlighting its distinct molecular configuration. | |||
== Related Pages == | |||
* [[AMPA receptor]] | |||
* [[Ionotropic glutamate receptor]] | |||
* [[Neuroprotection]] | |||
* [[Excitotoxicity]] | |||
* [[Epilepsy]] | |||
[[Category:Neuroscience]] | |||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
[[Category: | [[Category:Chemical compounds]] | ||
Latest revision as of 03:31, 13 February 2025
GYKI 52466[edit]
GYKI 52466 is a chemical compound known for its role as a non-competitive AMPA receptor antagonist. It is primarily used in neuroscience research to study the effects of AMPA receptor inhibition on synaptic transmission and neuroprotection.
Mechanism of Action[edit]
GYKI 52466 functions by binding to the AMPA receptor, a type of ionotropic glutamate receptor in the central nervous system. Unlike competitive antagonists, GYKI 52466 does not compete with glutamate for binding at the receptor's active site. Instead, it binds to an allosteric site, causing a conformational change that reduces the receptor's activity. This non-competitive inhibition results in decreased excitatory synaptic transmission, which can be beneficial in conditions characterized by excessive neuronal excitation.
Applications in Research[edit]
In neuroscience research, GYKI 52466 is utilized to explore the role of AMPA receptors in various physiological and pathological processes. It has been instrumental in studies investigating epilepsy, ischemic stroke, and neurodegenerative diseases such as Alzheimer's disease. By inhibiting AMPA receptor activity, researchers can assess the contribution of these receptors to neuronal excitotoxicity and cell death.
Potential Therapeutic Uses[edit]
The neuroprotective properties of GYKI 52466 have sparked interest in its potential therapeutic applications. In preclinical models, it has shown promise in reducing neuronal damage following ischemic events and in mitigating seizure activity. However, further research is needed to evaluate its safety and efficacy in humans.
Chemical Properties[edit]
GYKI 52466 is a member of the 2,3-benzodiazepine family, characterized by its unique chemical structure that allows for selective inhibition of AMPA receptors. The compound's structure is depicted in the accompanying image, highlighting its distinct molecular configuration.
